Valuation: DMS

Market Cap 28.12M 31.97M 26.12M 24.02M 45.05M 3.1B 45.86M 312M 122M 1.51B 120M 117M 5.24B P/E 2026 *
36.2x
P/E 2027 * 10.9x
Enterprise Value 43.52M 49.48M 40.43M 37.18M 69.73M 4.79B 70.98M 483M 189M 2.34B 186M 182M 8.11B EV / Sales 2026 *
0.77x
EV / Sales 2027 * 0.55x
Free-Float
69.9%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 18/07/2022
Director of Finance/CFO - 01/01/2022
Chief Tech/Sci/R&D Officer - 01/01/2019
Director TitleAgeSince
Chairman 53 18/07/2022
Director/Board Member 52 16/06/2025
Director/Board Member - 24/07/2023
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 32.39M
+0.01%+4.45%-14.78%-16.59% 13.79B
+1.52%-8.34%+40.09%-8.60% 3.89B
-0.23%-4.00%+64.67%+106.92% 1.2B
-3.05%-2.34%-38.13%-60.52% 1.21B
+0.19%-2.78%-41.32%-47.39% 1.09B
+0.34%+2.35%-42.93% - 934M
+2.37%-14.11%+49.28%+79.71% 457M
-4.49%+3.29%+55.29% - 345M
-0.21%+0.88%-58.49%+234.80% 262M
Average -0.35%+1.06%+1.52%+41.19% 2.57B
Weighted average by Cap. +0.09%+2.21%-3.25%-7.33%

Financials

2026 *2027 *
Net sales 56.8M 64.58M 52.77M 48.53M 91.01M 6.25B 92.64M 631M 246M 3.05B 242M 237M 10.58B 65.9M 74.93M 61.22M 56.31M 106M 7.26B 107M 732M 286M 3.54B 281M 275M 12.28B
Net income 800K 910K 743K 684K 1.28M 88.09M 1.3M 8.89M 3.47M 42.97M 3.41M 3.34M 149M 2.6M 2.96M 2.42M 2.22M 4.17M 286M 4.24M 28.88M 11.27M 140M 11.1M 10.86M 484M
Net Debt 15.4M 17.51M 14.31M 13.16M 24.68M 1.7B 25.12M 171M 66.73M 827M 65.74M 64.31M 2.87B 8M 9.1M 7.43M 6.84M 12.82M 881M 13.05M 88.87M 34.66M 430M 34.15M 33.41M 1.49B
Logo DMS
Diagnostic Medical Systems (DMS) is France's leader in the development, design, and production of imaging systems for digital and conventional radiology and osteodensitometry. The group's activity is organized around two sectors: - radiology equipment and osteodensitometers sales: mobile radiology units, floating table tops, operating room mobile amplifiers, ultrasound osteodensitometers (designed to chart the bone micro-architecture) and X ray osteodensitometers (designed to measure bone density), etc. The group also proposes devices distribution and maintenance activities; - development of biotechnology solutions: in the fields of arthrosis treatment and regenerative medicine. Products and services are marketed primarily by exclusive retailers. Net sales (not including sold divisions) are distributed geographically as follows: Europe (49.6%), North and South America (17%), Asia (7.5%), Middle East (7.5%), Africa (3.1%), Oceania (1%) and other (14.3%).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-